Suppr超能文献

苗勒氏抑制物质/抗苗勒氏管激素:一种治疗人类卵巢癌和其他癌症的潜在药物。

Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

机构信息

Massachusetts General Hospital, Boston, MA 02114, USA.

出版信息

Future Oncol. 2010 Mar;6(3):391-405. doi: 10.2217/fon.09.172.

Abstract

According to the 2008 American Cancer Society statistics, cancer remains the second leading cause of death in American today. Early detection, innovative surgery, new drugs and increased public education regarding avoidable risk factors, such as smoking, have had significant impact on the incidence and survival rates of many cancers, while overall death rates from all cancers have declined a modest 5% over the past 50 years. Ovarian cancer statistics, however, have not been as encouraging. Despite recent advances in the management of this disease, 5-year survival has not improved, and the search continues for rationally designed new treatments. Müllerian Inhibiting Substance is a strong candidate because it addresses many of the deficiencies of existing treatments. Namely, Müllerian Inhibiting Substance has little demonstrated toxicity, it complements the activity of known anticancer drugs, it is highly specific against cancers expressing its receptor and it inhibits the proliferation of drug-resistant tumors.

摘要

根据 2008 年美国癌症协会的统计数据,癌症仍然是当今美国的第二大死因。早期发现、创新手术、新药以及针对可避免的风险因素(如吸烟)的公众教育的增加,对许多癌症的发病率和存活率产生了重大影响,而过去 50 年来,所有癌症的总体死亡率仅下降了 5%。然而,卵巢癌的统计数据并不那么令人鼓舞。尽管最近在这种疾病的治疗方面取得了进展,但 5 年生存率并没有提高,人们仍在继续寻找合理设计的新治疗方法。Müllerian Inhibiting Substance 是一个强有力的候选者,因为它解决了现有治疗方法的许多缺陷。具体来说,Müllerian Inhibiting Substance 的毒性较小,它可以补充已知抗癌药物的活性,对表达其受体的癌症具有高度特异性,并抑制耐药肿瘤的增殖。

相似文献

2
An update on Mullerian-inhibiting substance: its potential application against ovarian cancer.
Endocr Relat Cancer. 2014 May 6;21(3):R227-33. doi: 10.1530/ERC-14-0030. Print 2014 Jun.
5
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. doi: 10.1073/pnas.0607959103. Epub 2006 Nov 6.
6
The role of mullerian inhibiting substance in female reproduction.
Curr Opin Obstet Gynecol. 2008 Jun;20(3):257-64. doi: 10.1097/GCO.0b013e3282fe99f2.
7
Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Gynecol Oncol. 2008 Jan;108(1):141-8. doi: 10.1016/j.ygyno.2007.09.010. Epub 2007 Nov 7.
9
The Anti-Mullerian hormone and ovarian cancer.
Hum Reprod Update. 2007 May-Jun;13(3):265-73. doi: 10.1093/humupd/dml060. Epub 2007 Jan 9.
10
[What's new in 2014 about anti-Müllerian hormone?].
J Gynecol Obstet Biol Reprod (Paris). 2014 Oct;43(8):559-71. doi: 10.1016/j.jgyn.2014.06.004. Epub 2014 Jul 17.

引用本文的文献

1
Anti-Müllerian hormone: biology and role in endocrinology and cancers.
Front Endocrinol (Lausanne). 2024 Sep 16;15:1468364. doi: 10.3389/fendo.2024.1468364. eCollection 2024.
3
Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms.
Cancers (Basel). 2024 Jun 20;16(12):2288. doi: 10.3390/cancers16122288.
5
The roles of anti-Müllerian hormone in breast cancer.
Endocr Relat Cancer. 2023 Aug 14;30(10). doi: 10.1530/ERC-23-0060. Print 2023 Oct 1.
6
Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.
Aging (Albany NY). 2021 Dec 13;13(23):25518-25549. doi: 10.18632/aging.203771.
7
Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211052154. doi: 10.1177/15330338211052154.
8
Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment.
Front Endocrinol (Lausanne). 2021 Sep 7;12:689532. doi: 10.3389/fendo.2021.689532. eCollection 2021.
10
Abnormal anti-Müllerian hormone level may be a trigger for breast cancer in young women: A case-control study.
Int J Reprod Biomed. 2021 Feb 21;19(2):181-190. doi: 10.18502/ijrm.v19i2.8476. eCollection 2021 Feb.

本文引用的文献

1
Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.
J Natl Cancer Inst. 2009 Nov 4;101(21):1501-9. doi: 10.1093/jnci/djp331. Epub 2009 Oct 9.
2
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).
Hum Reprod Update. 2010 Mar-Apr;16(2):113-30. doi: 10.1093/humupd/dmp036. Epub 2009 Sep 30.
4
The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors.
Int J Gynecol Cancer. 2009 Jul;19(5):847-55. doi: 10.1111/IGC.0b013e3181a702d1.
5
Anti-Mullerian hormone (AMH): what do we still need to know?
Hum Reprod. 2009 Sep;24(9):2264-75. doi: 10.1093/humrep/dep210. Epub 2009 Jun 11.
8
Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin.
J Cell Sci. 2008 Oct 15;121(Pt 20):3357-65. doi: 10.1242/jcs.031872. Epub 2008 Sep 16.
9
Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Gynecol Oncol. 2008 Jan;108(1):141-8. doi: 10.1016/j.ygyno.2007.09.010. Epub 2007 Nov 7.
10
The Anti-Mullerian hormone and ovarian cancer.
Hum Reprod Update. 2007 May-Jun;13(3):265-73. doi: 10.1093/humupd/dml060. Epub 2007 Jan 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验